Overview

IVIG in Painful Sensory Neuropathy

Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess effect of Intravenous immunoglobulins (antibodies) as compared to Placebo, on pain intensity in patients from 18-65 years with painful sensory neuropathy without a known cause. Effect of the treatment will be recorded by the patient in a digital diary.
Phase:
Phase 4
Details
Lead Sponsor:
Sorlandet Hospital HF
Collaborators:
Oslo University Hospital
University Hospital of North Norway
University Hospital of Saint-Etienne
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin